Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (2023 - 2025)

Monte Rosa Therapeutics' Shares Outstanding history spans 3 years, with the latest figure at $65.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 6.56% year-over-year to $65.5 million; the TTM value through Dec 2025 reached $65.5 million, up 6.56%, while the annual FY2025 figure was $65.5 million, 6.56% up from the prior year.
  • Shares Outstanding reached $65.5 million in Q4 2025 per GLUE's latest filing, up from $61.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $65.5 million in Q4 2025 to a low of $49.4 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $57.0 million, with a median of $61.4 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: rose 23.55% in 2024, then grew 0.63% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $50.1 million in 2023, then increased by 22.67% to $61.5 million in 2024, then rose by 6.56% to $65.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Shares Outstanding are $65.5 million (Q4 2025), $61.8 million (Q3 2025), and $61.7 million (Q2 2025).